Why IMU is a multi multi bagger, page-19797

Hi Kluck @Kluck

Its funny that you should mention and re-post an article announcing our RenovoRx collaboration.

In this collaboration, RenovoRx will investigate the ability to administer Imugene’s CF33 oncolytic virus technology
with RenovoRx’s TAMP therapy platform. The primary target ... Locally Advanced Pancreatic Cancer (LAPC),
an extremely difficult-to-access, solid tumor cancer.

Well, RenovoRx are deep into their Phase 3 Trans-Arterial Micro-Perfusion (TAMP) therapy trial and are clearly
seeing very positive signs. As a result they will be sharing their latest data cut at the 2024 SIR Meeting in March.

In my view, IMU may be able to 'strike at the core' of Pancreatic cancer using Renovo's TAMP process. As Kluck says,
"Another price sensitive announcement on (this collaboration) would be exciting." Perhaps more than exciting.

Looks like the news flow in 2024 may be huge (in a good way). Let's hope it has a positive effect on our SP.
I certainly think it will.

Opinion only

PS- Just noticed that the news is getting out.